The nanoparticle-based siRNA formulation, known as Patisiran (ONPATTROTM) targets transthyretin mRNA and is used for the treatment of polyneuropathy in a hereditary form of transthyretin-mediated (hATTR) amyloidosis (Wood, 2018). Here, TTR is linked to polyneuropathy.